NEW YORK (GenomeWeb News) – Epigenomics and VSA Alta Complejidad today announced that VSA has been approved to market Epigenomics' Epi proColon kit in Argentina.

The companies have worked together since last year to secure regulatory approval for Epigenomics' blood-based colorectal cancer test from ANMAT, which regulates diagnostic tests in Argentina. They also said that VSA has forged relationships with leading diagnostic reference laboratories in Argentina to make Epi proColon available there.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.